Treatment of ESBL-Producing Klebsiella pneumoniae Wound Infection

Antibiotic Selection Based on Susceptibility Results

The Infectious Diseases Society of America recommends carbapenems, such as ertapenem, imipenem, or meropenem, as the first-line treatment for ESBL-producing Klebsiella pneumoniae wound infections, based on susceptibility results 1, 2
The culture shows susceptibility to carbapenems, including ertapenem and imipenem, with a high clinical efficacy 1, 3
The organism shows resistance to fluoroquinolones, such as ciprofloxacin and levofloxacin, and ampicillin and ampicillin/sulbactam 3

The American College of Clinical Pharmacy recommends carbapenem monotherapy, with options including ertapenem 1g IV daily, imipenem 500mg IV every 6 hours, and meropenem 1g IV every 8 hours, as the preferred treatment for ESBL-producing infections 1, 5

Piperacillin/tazobactam may be considered as an alternative treatment option, despite controversy regarding its use in ESBL infections, at a dose of 4.5g IV every 6-8 hours 4
Aminoglycosides, such as amikacin, may be considered as part of combination therapy, at a dose of 15-20 mg/kg IV daily, based on susceptibility results 3, 4

The Infectious Diseases Society of America recommends 7-10 days of antibiotic therapy for wound infections with adequate debridement 1, 6
Treatment duration should be individualized based on clinical response, source control, and wound healing, with a recommended reassessment within 48-72 hours of initiating therapy 7, 6

Source control is critical, with proper wound debridement and drainage of any collections necessary to optimize treatment outcomes 8, 7
Fluoroquinolones should be avoided due to high clinical failure rates with ESBL-producing organisms, despite possible in vitro susceptibility 3, 4

Cephalosporins should not be used alone, despite in vitro susceptibility, due to the risk of clinical failure with ESBL-producing organisms 5
Beta-lactam/beta-lactamase inhibitor combinations, except possibly piperacillin/tazobactam, should not be relied upon as primary therapy for serious ESBL infections 4

Reassess wound healing and clinical response within 48-72 hours of initiating therapy, and consider repeat cultures if clinical improvement is not observed 8, 4
Monitor renal function if using aminoglycosides, such as amikacin, due to the risk of nephrotoxicity 1